Only Regulatory Products (API/FDF), Drugs in Developments and News are Updated on this Virtual Booth
Update your Virtual Booth on PharmaCompass, ask us
About
Not Confirmed
Not Confirmed
26-28 August, 2025
Not Confirmed
Not Confirmed
24-25 July, 2025
BIO Asia-TaiwanBIO Asia-Taiwan
Not Confirmed
Not Confirmed
24-27 July, 2025
List your booth number for exhibitions, ask us
CONTACT DETAILS
Upload your Marketing & Sales content on your company Virtual Booth, click HERE.
Events
Webinars & Exhibitions
Industry Trade Show
Not Confirmed
26-28 August, 2025
Industry Trade Show
Not Confirmed
24-25 July, 2025
BIO Asia-TaiwanBIO Asia-Taiwan
Industry Trade Show
Not Confirmed
24-27 July, 2025
Digital content
INTERVIEW #SpeakPharma
[Sponsored by another company]https://www.pharmacompass.com/speak-pharma/50-years-of-innovation-mikart-s-legacy-and-what-s-next-in-cdmo-excellence
VLOG #PharmaReel
[Sponsored by another company]DATA COMPILATION #PharmaFlow
[Sponsored by another company]https://www.pharmacompass.com/radio-compass-blog/cdmo-activity-tracker-veranova-carbogen-lead-adc-investments-axplora-polfa-tarchomin-famar-expand-european-footprint
27 Jun 2025
// BUSINESSWIRE
https://www.businesswire.com/news/home/20250627829521/en/Omeros-Submits-Narsoplimab-Marketing-Authorization-Application-to-the-European-Medicines-Agency-for-the-Treatment-of-TA-TMA
24 Jun 2025
// BUSINESSWIRE
https://www.businesswire.com/news/home/20250624677872/en/Omeros-Announces-Webcast-Details-for-Annual-Meeting-of-Shareholders
15 May 2025
// BUSINESSWIRE
https://www.businesswire.com/news/home/20250515277934/en/Omeros-Corporation-Reports-First-Quarter-2025-Financial-Results
12 May 2025
// BUSINESSWIRE
https://www.businesswire.com/news/home/20250512044570/en/Omeros-Corporation-to-Announce-First-Quarter-Financial-Results-on-May-15-2025
12 May 2025
// BUSINESSWIRE
https://www.businesswire.com/news/home/20250509242099/en/Omeros-Corporation-Announces-Agreements-to-Acquire-%2480.5-Million-of-its-Convertible-Senior-Notes-Due-2026
07 May 2025
// BUSINESSWIRE
https://www.businesswire.com/news/home/20250506308278/en/FDA-Accepts-Resubmission-of-BLA-for-Narsoplimab-for-Hematopoietic-Stem-Cell-Transplant-Associated-Thrombotic-Microangiopathy-TA-TMA-and-Assigns-Late-September-PDUFA-Date
ABOUT THIS PAGE